![logo](/logos/OKYO.webp)
OKYO Pharma Limited
NASDAQ:OKYO
1.36 (USD) • At close July 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | OKYO Pharma Limited |
Symbool | OKYO |
Munteenheid | USD |
Prijs | 1.361 |
Beurswaarde | 51,935,633 |
Dividendpercentage | 0% |
52-weken bereik | 1.09 - 3.07 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gary S. Jacob Ph.D. |
Website | https://www.okyopharma.com |
An error occurred while fetching data.
Over OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)